drugset / Trial / NCT00415038

Efficacy of Rostafuroxin in the Treatment of Essential Hypertension

NCT00415038

Phase 2 Completed 438 enrolled sigma-tau i.f.r. S.p.A.
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to verify the efficacy of Rostafuroxin in the treatment of essential hypertension and to determine the best effective dose to be administered in the general hypertensive population and in a subset of this population in which genetic patterns could be involved in the etiology of essential hypertension.

Timeline

Start
2005-02
Primary completion
2007-04
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Rostafuroxin Small molecule 50 ug
Subject Rostafuroxin Small molecule 150 ug
Subject Rostafuroxin Small molecule 500 ug
Subject Rostafuroxin Small molecule 1.5 mg
Subject Rostafuroxin Small molecule 5 mg